STI Stock Trade Intelligence
PIQ

PROTEOMICS INTERNATIONAL LABORATORIES LTD

Health Care · ASX:PIQ
$0.1000
▲ +2.04%
Market cap
$17M
Turnover
$9,889
Last price
$0.1000
Day change
+2.04%
Announcements
14
Range, past year
Open 0.330 · Low 0.090 · Now 0.100 · High 0.860
Open PIQ in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

PIQ momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-11-16.
Momentum quality
32/100
Wyckoff phase
Downtrend11d
Trend stage
Neutral
1 Day
+2.0%
1 Week
+4.2%
1 Month
-16.7%
1 Year
-70.6%
RSI
42
Avg daily range
7.1%

PROTEOMICS INTERNATIONAL LABORATORIES LTD scores 32 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Downtrend, where it has been for 11 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.87 — highly linear uptrend
Points to watch
  • 60d drawdown -44.8%
  • High volatility (ATR 7.1%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

PIQ announcements

Recent price-sensitive releases.
  • 2026-10-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
  • 2026-10-23 National Rollout of PromarkerD and PromarkerEso Progress Report
  • 2026-10-21 Proteomics International receives $2.0m in R&D tax incentive Company Administration - Other
  • 2026-10-13 PromarkerEndo Validation and Refinement Complete Progress Report
  • 2026-09-14 PromarkerD and PromarkerEso Commercial Rollout Update Progress Report
  • 2026-08-31 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-08-13 Australian patent for PromarkerEndo Progress Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.